Zogenix, Inc. (ZGNX) News
Filter ZGNX News Items
ZGNX News Results
|Loading, please wait...|
ZGNX News Highlights
- For ZGNX, its 30 day story count is now at 10.
- Over the past 27 days, ZGNX's stories per day has been in a clear downtrend, falling by about 0.29 per 6 days.
- The most mentioned tickers in articles about ZGNX are RARE, DS and PLUG.
Latest ZGNX News From Around the Web
Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.
Zogenix (ZGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Dravet Syndrome Treatment Market Aims to Expand at Double-Digit Growth Rate | Zogenix, GW Pharmaceuticals
To make market focusing on and deals exercises simpler, this Dravet Syndrome Treatment market report focuses on key market fragments. It will likewise assist you with drawing in various sorts of clients by advancing significant strategies. This Dravet Syndrome Treatment
If the high-water price target for each of the following five stocks were to come to fruition, shareholders would be looking at gains ranging from a low of 195% to as much as 467%. If you're "only" looking to triple your money, analyst Amit Dayal of H.C. Wainwright would suggest putting it to work in hydrogen fuel-cell solutions company Plug Power (NASDAQ: PLUG). Dayal's price target of $78 implies a cool 195% upside from where its shares closed this past weekend.
Since the end of the Great Recession in 2009, growth stocks have thrived. For each of the following hypergrowth stocks, Wall Street's consensus sales estimate for 2023, courtesy of FactSet, implies a revenue increase ranging from a low of 1,185% (yes, a low of 1,185%) to a high of 12,629%, compared to 2020 sales. Arguably the best-known name on this list is biotech Moderna (NASDAQ: MRNA).
Global Dravet Syndrome (DS) Market Analysis, Scope and Forecast By 2021-2027. The IBI Updates I Top key players-Ovid Therapeutics/Takeda, PTC Therapeutics and Zogenix & Others
The research provided by Infinity Business Insights provides a thorough explanation of the disease as well as DS market trends in several locations. It examines multiple studies and the perspectives of important opinion leaders to assist identify the reasons of
Zogenix plans to submit a new drug application (J-NDA) for FINTEPLA in Japan for the treatment of seizures associated with Dravet syndrome by year end. Dravet syndrome is a rare, life-long form of epilepsy marked by severe seizures, significant developmental delays, frequent hospitalizations and medical emergencies, and increased risk of premature death . Seizures associated with Dravet syndrome are highly resistant to existing anti-epileptic medicines, pointing to a major need for new treatment options. EMERYVILLE, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX ), a global biopharmaceutical company developing rare disease therapies, today announced that the Japanese Ministry of Health, Labour & Welfare (MHLW) has granted Orphan Drug Designation to FINTEPLA® (fenflurami...
EMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the companys board of directors granted inducement awards to fourteen new employees. The awards were made on August 15, 2021, under Zogenixs 2021 Employment Inducement Equity Incentive Award Plan, which was approved by the companys board of directors under Nasdaq Marketplace Rule 5635(c)(4), for granting equity awards to new employees of Zogenix as an inducement to join the company. The awards consist of options to purchase an aggregate of 34,580 shares of Zogenix common stock and 17,340 restricted stock units. The options have a ten year term and an exercise price equal to $13.75, the closing price per share of the common stock on August 13, 2021, and vest ove...
Trade Alert: The Co-founder & Independent Chairman Of Zogenix, Inc. (NASDAQ:ZGNX), Cam Garner, Has Just Spent US$148k Buying 14% More Shares
Potential Zogenix, Inc. ( NASDAQ:ZGNX ) shareholders may wish to note that the Co-founder & Independent Chairman, Cam...
Let’s talk about buying low. It’s the starting point to buying low and selling high, of course, the clichéd path toward profits. But the thing about clichés is, they usually have a core of truth. And if you buy at a low price, and sell at a high price, you’ve made a profit. The trick, for investors, is recognizing the low price, the point of entry. Conventional wisdom would suggest avoiding stocks whose share prices have bottomed out – after all, low prices happen for a reason, and share sell-of
EMERYVILLE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three and six months ended June 30, 2021, and provided a corporate update. The Company will host a conference call today, Thursday, August 5, at 4:30 PM Eastern Time/1:30 PM Pacific Time.